GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Renal | QC | Active, not recruiting
89ZR-TLX250
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (89ZR-TLX250)
Telix International Pty Ltd.
Start Date: August 15, 2019

NCT #: NCT03849118

SPONSOR: Telix Phamaceuticals

INFO: https://clinicaltrials.gov/ct2/show/NCT03849118?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=10

CONTACT:  Canadian Site Contact (CHUQ): 418-525-4444

OTHER CANADIAN CENTRES: CHU de Quebec - Universite Laval (Quebec City)

 

Renal | AB, ON | Active, not recruiting
CVPM087A2101
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers.
Novartis Pharmaceuticals
Start Date: May 19, 2019

NCT #: NCT03798626

SPONSOR: Novartis Pharmaceuticals

INFO: https://clinicaltrials.gov/ct2/show/NCT03798626?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=8

CONTACT: 1-888-669-6682

OTHER CANADIAN CENTRES: 

Tom Baker Cancer Centre (Calgary), Cross Cancer Institute (Edmonton), University Health Network (Toronto)

 

Renal | ON | Recruiting
REMEDY
Renal Cell Carcinoma Microenvironment Discovery Project
Dr. Antonio Finelli (UHN) - Toronto
Start Date: May 6, 2019

NCT #: NCT04005183

SPONSOR: UHN in Collaboration with Celsus Therapeutics PLC

INFO: https://clinicaltrials.gov/ct2/show/NCT04005183?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=1

CONTACT:  416-946-2851

Prostate | BC, MB, NS, ON, QC | Recruiting
PR20
A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
Dr. Patrick C.F. Cheung (Odette Cancer Centre) & Dr. M. Tamim Niazi (JGH)
Start Date: April 18, 2019

NCT#:  NCT02960087

INFO: https://clinicaltrials.gov/ct2/show/NCT03784755

CONTACT:

(416) 480-6165

(514) 340-8288

 

Bladder | ON | Recruiting
SL01-DEL-101
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Dr. Lini Pandie & Dr. Fatima Rangwala
Start Date: March 26, 2019

NCT #: NCT03894618

SPONSOR: Shattuck Labs, Inc. 

INFO: https://clinicaltrials.gov/ct2/show/NCT03894618?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=9

CONTACT: 984-329-5231

OTHER CANADIAN CENTRES:

1. Princess Margaret Cancer Center (Toronto): Lillian.Siu@uhn.ca

 

Renal | ON | Recruiting
SL01-DEL-101
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Start Date: March 26, 2019

NCT #:  NCT03894618

SPONSOR: Shattuck Labs, Inc.

INFO:   https://clinicaltrials.gov/ct2/show/NCT03894618?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2

CONTACT: Princes Margaret Cancer Center (Toronto) // Lillian.Siu@uhn.ca

OTHER CANADIAN CENTRES:  PMH (Toronto)

Bladder | ON | Active, not recruiting
NCI-2019-01035, ETCTN 10183
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
Dr. Di Maria Jiang (UHN Lead)
Start Date: March 17, 2019

NCT #: NCT03854474

SPONSOR: National Cancer Institute (NCI)

INFO: https://clinicaltrials.gov/ct2/show/NCT03854474?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=3

CONTACT:  416-946-4501

 

Renal | ON | Recruiting
3D Ultrasound
(3D) Ultrasound Imaging Liver and Kidney
Dr. Aaron Fenster
Start Date: February 18, 2019

NCT #: NCT03844399

SPONSOR: Western University (London)

INFO: https://clinicaltrials.gov/ct2/show/NCT03844399?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=4

CONTACT:  519-931-5777

Bladder | AB, BC, ON, QC, SK | Recruiting
BL13
A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer
Dr. Wassim Kassouf (MUHC)
Start Date: December 21, 2018

NCT #: NCT03768570

SPONSOR: CCTG in collaboration with AstraZeneca

INFO: https://clinicaltrials.gov/ct2/show/NCT03768570

CONTACT: (514) 934-8246

OTHER CANADIAN CENTRES:

1. Tom Baker Cancer Centre (Calgary): 403-521-3445                                                         
2. Cross Cancer Institute (Edmonton): 780-432-8762                                                                    
3. BCCA Vancouver Cancer Centre: 604-877-6000                                                                        
4. Juravinski Cancer Centre (Hamilton): 905-387-9495                                                                                
5. Kingston Health Sciences Centre: 613-533-6463 x 78769                                                 
6. London Regional Cancer Program: 519-685-8261                                                       
7. Stronach Regional Health Centre (Newmarket): 905-685-4521 x 6596                                           
8. Ottawa Hospital Research Institute: 613-737-7700 x 70180                                             
9. Health Sciences North (Sudbury): 705-522-6237                                                        
10. Thunder Bay Regional Health Sciences Centre: 807-684-7566                                      
11. University Health Network (Toronto): 416-946-4501 x 2520                                 
12. The Jewish General Hospital (Montreal): 514-398-8307                                        
13. The Research Institute of McGill University (Montreal): 514-934-8246                     
14. Allan Blair Cancer Centre (Regina): 306-755-2691                                                         
15. Saskatoon Cancer Centre: 306-655-2710                                                         
 

Prostate | QC | Recruiting
2019-4650
Single Fractions SBRT for Prostate Cancer
Dr. Fabio Cury
Start Date: November 8, 2018

NCT #: NCT04004312

SPONSOR: McGill University Health Centre in collaboration with Boston Scientific Corporation

INFO: https://clinicaltrials.gov/ct2/show/NCT04004312

CONTACT:  514-934-1934 ext 43191

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy